Cellink AB (CLNK B):企業の財務・戦略的SWOT分析

◆英語タイトル:Cellink AB (CLNK B) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH3446624FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Cellink AB (CLNK B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cellink AB (Cellink) develops and commercializes bioprinting technologies which enable researchers to print three dimensional (3D) human organs and tissues. The company’s product portfolio encompasses bioprinters which enable bioprinting of human tissues and tissue models for 3D culture in advanced research; and bioink, a biomaterial innovation that allows researchers to develop and grow 3D human cells to grow as they do in the natural human body environment. Cellink caters to research institutions, pharmaceutical, biopharmaceutical, automotive, and cosmetic companies. The company sells its products through direct sales force in the US and Sweden and through an extensive network of distributors in Europe (excluding Sweden), and Asia-Pacific. It operates a subsidiary in the US. Cellink AB is headquartered in Goteborg, Sweden.

Cellink AB Key Recent Developments

Mar 15,2021: Cellink launches the Bio Mdx Series, a scaled-up revolution in biomedical manufacturing
Mar 11,2021: Cellink announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
Feb 08,2021: CELLINK announce distribution agreement including new products for Single-Cell RNA Sequencing and NGS Library Preparation
Jan 28,2021: CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery
Nov 27,2020: CELLINK welcomes new scientific advisor Professor Robert Langer from MIT and co-founder of Moderna

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Cellink AB – Key Facts
Cellink AB – Key Employees
Cellink AB – Key Employee Biographies
Cellink AB – Major Products and Services
Cellink AB – History
Cellink AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Cellink AB – Business Description
R&D Overview
Cellink AB – Corporate Strategy
Cellink AB – SWOT Analysis
SWOT Analysis – Overview
Cellink AB – Strengths
Cellink AB – Weaknesses
Cellink AB – Opportunities
Cellink AB – Threats
Cellink AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Cellink AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cellink AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cellink AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 15, 2021: Cellink launches the Bio Mdx Series, a scaled-up revolution in biomedical manufacturing
Mar 11, 2021: Cellink announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
Feb 08, 2021: CELLINK announce distribution agreement including new products for Single-Cell RNA Sequencing and NGS Library Preparation
Jan 28, 2021: CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery
Nov 27, 2020: CELLINK welcomes new scientific advisor Professor Robert Langer from MIT and co-founder of Moderna
Oct 22, 2020: Cellink: Strong organic growth and important strategic acquisition under continued challenging conditions
Oct 21, 2020: CELLINK launches C.WASH, an innovative liquid handling system for automated media change in micro-well plates
Aug 28, 2020: CELLINK welcomes new scientific advisor Professor Ido Amit from the Weizmann Institute of Science
Jul 14, 2020: CELLINK and Kugelmeiers announce strategic partnership for 3D printing cell spheroids
Jul 09, 2020: Cellink – Q3 19/20: Continued growth and main market listing during an ongoing pandemic
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Cellink AB, Key Facts
Cellink AB, Key Employees
Cellink AB, Key Employee Biographies
Cellink AB, Major Products and Services
Cellink AB, History
Cellink AB, Other Locations
Cellink AB, Subsidiaries
Cellink AB, Key Competitors
Cellink AB, Ratios based on current share price
Cellink AB, Annual Ratios
Cellink AB, Annual Ratios (Cont...1)
Cellink AB, Annual Ratios (Cont...2)
Cellink AB, Interim Ratios
Cellink AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cellink AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cellink AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Cellink AB (CLNK B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Regeneron Pharmaceuticals Inc (REGN):企業の製品パイプライン分析
    Summary Regeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, meta …
  • Molnlycke Health Care AB-医療機器分野:企業M&A・提携分析
    Summary Molnlycke Health Care AB (Molnlycke) a subsidiary of Investor AB, is a medical device company. The company carries out the manufacturing and marketing of single-use surgical and wound care products. The company offers a range of surgical and wound care products; infection prevention solution …
  • Ultragenyx Pharmaceutical Inc (RARE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. Its only marketed product, Mepsevii (vestronidase alfa) is the first indication approved for the treatment of adults and children with Muc …
  • Cantabio Pharmaceuticals Inc (CTBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Cantabio Pharmaceuticals Inc (Cantabio Pharmaceuticals) is a biotechnology company that concentrates on the commercializing of novel therapies for Parkinson’s disease, Alzheimer’s disease and neurodegenerative diseases. The company provide pipeline product candidates such as CB101 and CB102, …
  • Admiral Taverns Ltd:企業の戦略・SWOT・財務分析
    Admiral Taverns Ltd - Strategy, SWOT and Corporate Finance Report Summary Admiral Taverns Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ophthotech Corp (OPHT):企業の財務・戦略的SWOT分析
    Summary Ophthotech Corp (Ophthotech) is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt disease. It also provides Fovista, a …
  • Nippon Chemiphar Co Ltd (4539):企業の財務・戦略的SWOT分析
    Summary Nippon Chemiphar Co Ltd (Nippon Chemiphar) is a provider of pharmaceutical drugs and health-related services. The company manufactures, supplies, imports and exports ethical pharmaceuticals and diagnostic agents. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides r …
  • Contact Energy Limited:企業の戦略・SWOT・財務情報
    Contact Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Contact Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • GE Healthcare:企業のM&A・事業提携・投資動向
    GE Healthcare - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GE Healthcare Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Pro-Dex Inc (PDEX)-医療機器分野:企業M&A・提携分析
    Summary Pro-Dex Inc (Pro-Dex) is a medical device company that manufactures and markets surgical devices. The company’s products comprise motion control, finished medical devices, plastic injection molding, micro air-motors, dental products, and torque wrenches. Its dental products include DLS handp …
  • T3D Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary T3D Therapeutics Inc (T3D) is a developer of solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. It provides a potential to improve …
  • Hanmi Pharmaceuticals Co Ltd (128940):医療機器:M&Aディール及び事業提携情報
    Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counte …
  • Northern Technologies International Corporation (NTIC):企業の財務・戦略的SWOT分析
    Northern Technologies International Corporation (NTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • European Institute of Oncology-製薬・医療分野:企業M&A・提携分析
    Summary European Institute of Oncology (IEO) is a research institute that conducts clinical and scientific research on cancer prevention, early diagnosis and treatment of cancer. The institute offers medical care services for breast tumors, lung tumors, cervical tumors, endometrial tumors, thoracic …
  • Abreos Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Abreos Biosciences Inc (Abreos) is a biotechnology company with focus on the development of laboratory-based and point-of-care (POC) assays and reagents for the precision dose monitoring of biologic drugs. Its Monator, is a drug-monitoring test that provides physicians with vital information …
  • Vulcan Minerals Inc (VUL):企業の財務・戦略的SWOT分析
    Summary Vulcan Minerals Inc (Vulcan) is an oil and gas exploration company. The company acquires and develops petroleum and natural gas properties. The company's Springdale project consist all the properties on the Springdale peninsula and operates the Colchester, Pine Pond and Little Bay Mine proje …
  • Orica Ltd:企業の戦略・SWOT・財務分析
    Orica Ltd - Strategy, SWOT and Corporate Finance Report Summary Orica Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Arotech Corporation:企業の戦略・SWOT・財務情報
    Arotech Corporation - Strategy, SWOT and Corporate Finance Report Summary Arotech Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Jordan Phosphate Mines Co. Plc.:企業の戦略・SWOT・財務情報
    Jordan Phosphate Mines Co. Plc. - Strategy, SWOT and Corporate Finance Report Summary Jordan Phosphate Mines Co. Plc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Clinicient Inc-医療機器分野:企業M&A・提携分析
    Summary Clinicient Inc (Clinicient) is a healthcare technology company that offers EMR management and therapy practice solutions. The company offers insight platform software that offers single system created exclusively for outpatient rehab that populates data across both the clinical and financial …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆